PURPOSE: To document the incidence and timing of radiotherapy-induced nausea and vomiting (RINV) in the treatment of bone metastases among patients receiving prophylaxis with a 5-HT(3) receptor antagonist. METHODS: Patients receiving single (SF) or multiple fraction (MF) palliative radiotherapy (RT) of moderate or low emetogenic risk for bone metastases were prescribed prophylactic Ondansetron. The frequency and duration of prophylaxis and the use of rescue antiemetics were left to the discretion of the treating physicians. Patients documented episodes of nausea (N) and vomiting (V) in daily diaries before and during RT, and until 10 days following RT completion. Rates of complete prophylaxis (CP) for N&V, respectively (CP = no event and no rescue medication), were calculated for the acute phase (the period from the start of RT to the first day following RT completion inclusive) and the delayed phase (the second to tenth days following RT completion inclusive). RESULTS: Fifty-nine patients were enrolled, and 32 were evaluable. CP rates were as follows: moderate-risk SF group (n = 16), acute phase (CP for N = 56%, CP for V = 69%) and delayed phase (CP for N = 31%, CP for V = 44%); moderate-risk MF group (n = 7), acute phase (CP for N = 71%, CP for V = 57%) and delayed phase (CP for N = 43%, CP for V = 57%); low-risk SF group (n = 8), acute phase (CP for N = 50%, CP for V = 100%) and delayed phase (CP for N = 43%, CP for V = 57%); and low-risk MF group (n = 1), acute phase (CP for N = 100%, CP for V = 100%) and delayed phase (CP for N = 100%, CP for V = 100%). CONCLUSIONS: Despite prophylaxis, RINV was common among patients receiving palliative radiotherapy for bone metastases, especially during the delayed phase.
PURPOSE: To document the incidence and timing of radiotherapy-induced nausea and vomiting (RINV) in the treatment of bone metastases among patients receiving prophylaxis with a 5-HT(3) receptor antagonist. METHODS:Patients receiving single (SF) or multiple fraction (MF) palliative radiotherapy (RT) of moderate or low emetogenic risk for bone metastases were prescribed prophylactic Ondansetron. The frequency and duration of prophylaxis and the use of rescue antiemetics were left to the discretion of the treating physicians. Patients documented episodes of nausea (N) and vomiting (V) in daily diaries before and during RT, and until 10 days following RT completion. Rates of complete prophylaxis (CP) for N&V, respectively (CP = no event and no rescue medication), were calculated for the acute phase (the period from the start of RT to the first day following RT completion inclusive) and the delayed phase (the second to tenth days following RT completion inclusive). RESULTS: Fifty-nine patients were enrolled, and 32 were evaluable. CP rates were as follows: moderate-risk SF group (n = 16), acute phase (CP for N = 56%, CP for V = 69%) and delayed phase (CP for N = 31%, CP for V = 44%); moderate-risk MF group (n = 7), acute phase (CP for N = 71%, CP for V = 57%) and delayed phase (CP for N = 43%, CP for V = 57%); low-risk SF group (n = 8), acute phase (CP for N = 50%, CP for V = 100%) and delayed phase (CP for N = 43%, CP for V = 57%); and low-risk MF group (n = 1), acute phase (CP for N = 100%, CP for V = 100%) and delayed phase (CP for N = 100%, CP for V = 100%). CONCLUSIONS: Despite prophylaxis, RINV was common among patients receiving palliative radiotherapy for bone metastases, especially during the delayed phase.
Authors: Petra Ch Feyer; Ernesto Maranzano; Alexander Molassiotis; Rebecca A Clark-Snow; Fausto Roila; David Warr; Ian Olver Journal: Support Care Cancer Date: 2004-12-08 Impact factor: 3.603
Authors: Mark G Kris; Paul J Hesketh; Mark R Somerfield; Petra Feyer; Rebecca Clark-Snow; James M Koeller; Gary R Morrow; Lawrence W Chinnery; Maurice J Chesney; Richard J Gralla; Steven M Grunberg Journal: J Clin Oncol Date: 2006-05-22 Impact factor: 44.544
Authors: Rebecca K S Wong; Nancy Paul; Keyue Ding; Marlo Whitehead; Michael Brundage; Anthony Fyles; Derek Wilke; Abdenour Nabid; Andre Fortin; Don Wilson; Michael McKenzie; Ida Ackerman; Luis Souhami; Pierre Chabot; Joseph Pater Journal: J Clin Oncol Date: 2006-07-20 Impact factor: 44.544
Authors: Ernesto Maranzano; Verena De Angelis; Stefano Pergolizzi; Marco Lupattelli; Paolo Frata; Stefano Spagnesi; Maria Luisa Frisio; Giovanni Mandoliti; Giuseppe Malinverni; Fabio Trippa; Letizia Fabbietti; Salvatore Parisi; Annamaria Di Palma; Pietro De Vecchi; Costantino De Renzis; Celestino Giorgetti; Tiziano Bergami; Roberto Orecchia; Maurizio Portaluri; Marco Signor; Davide Di Gennaro Journal: Radiother Oncol Date: 2009-12-04 Impact factor: 6.280
Authors: Anna Enblom; Beata Bergius Axelsson; Gunnar Steineck; Mats Hammar; Sussanne Börjeson Journal: Support Care Cancer Date: 2008-06-05 Impact factor: 3.603
Authors: Christina H Ruhlmann; Franziska Jahn; Karin Jordan; Kristopher Dennis; Ernesto Maranzano; Alexander Molassiotis; Fausto Roila; Petra Feyer Journal: Support Care Cancer Date: 2016-09-13 Impact factor: 3.603
Authors: Michael Poon; Kristopher Dennis; Carlo DeAngelis; Hans Chung; Jordan Stinson; Liying Zhang; Gillian Bedard; Marko Popovic; Nicholas Lao; Natalie Pulenzas; Shun Wong; Edward Chow Journal: Support Care Cancer Date: 2014-01-12 Impact factor: 3.603
Authors: E Wong; N Pulenzas; G Bedard; C DeAngelis; L Zhang; M Tsao; C Danjoux; N Thavarajah; B Lechner; R McDonald; P M Cheon; E Chow Journal: Curr Oncol Date: 2015-06 Impact factor: 3.677
Authors: K Dennis; C De Angelis; F Jon; N Lauzon; M Pasetka; L Holden; E Barnes; C Danjoux; A Sahgal; M Tsao; E Chow Journal: Curr Oncol Date: 2014-12 Impact factor: 3.677
Authors: Paulien G Westhoff; Alexander de Graeff; Evelyn M Monninkhof; Ilse de Pree; Marco van Vulpen; Jan Willem H Leer; Corrie A M Marijnen; Yvette M van der Linden Journal: J Radiat Oncol Date: 2017-09-19
Authors: Robert Olson; Roel Schlijper; Nick Chng; Quinn Matthews; Marco Arimare; Lindsay Mathews; Fred Hsu; Tanya Berrang; Alexander Louie; Benjamin Mou; Boris Valev; Joanna Laba; David Palma; Devin Schellenberg; Shilo Lefresne Journal: BMC Cancer Date: 2019-10-28 Impact factor: 4.430